CDK12-IN-3

CAS No. 2220184-50-7

CDK12-IN-3( —— )

Catalog No. M33320 CAS No. 2220184-50-7

CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 201 Get Quote
5MG 312 Get Quote
10MG 511 Get Quote
25MG 1040 Get Quote
50MG 1739 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CDK12-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.
  • Description
    CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2220184-50-7
  • Formula Weight
    470.52
  • Molecular Formula
    C23H28F2N8O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (531.33 mM; Ultrasonic )
  • SMILES
    CC(C)n1cnc2c(NCc3nc4ccc(F)c(F)c4[nH]3)nc(nc12)N1CCCC[C@H]1CCO
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Johannes JW, et al. Structure-Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem. 2018 Feb 6;13(3):231-235.?
molnova catalog
related products
  • XPW1

    XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.

  • CDK8-IN-1

    CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).

  • CDK9-IN-7

    CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).